title: Effect of 48-week pegylated interferon α-2a or nucleos(t)ide analogue therapy on renal function in Chinese patients with chronic hepatitis B.
abstract: Controversy remains as to whether antiviral agents contribute to renal dysfunction in patients with chronic hepatitis B virus (HBV) infection. Thus, the aim of study was to analyze the changes in renal function of chronic hepatitis B (CHB) patients in response to anti-HBV therapy and the association with treatments.
  
  
  
  We performed a retrospective observational cohort study to investigate factors associated with renal function in 249 Chinese CHB patients who were treated with pegylated interferon α-2a (PEG-IFN-α-2a) or nucleos(t)ide analogues for 48 weeks. Changes of estimated glomerular filtration rate (eGFR), which was computed with both the Chronic Kidney Disease Epidemiology Collaboration and the Modification of Diet in Renal Disease formulas, were tested by repeated measures One-way analysis of variance within groups. A linear mixed effects model for repeated measures was also used to evaluate the association between baseline information and eGFR changes over time in all enrolled patients. The model considered the baseline age, sex, HBV DNA, aminotransferase, blood urea nitrogen, treatment group, time, and group-by-time interaction as fixed effects and incorporated random effects for individual subjects.
  
  
  
  The eGFR increased in patients given PEG-IFN-α-2a, decreased in patients given adefovir, but remained stable in patients given entecavir. Age and blood urea nitrogen were significant negative predictive factors for eGFR changes.
  
  
  
  In real-life study, PEG-IFN-α-2a therapy in CHB patients increased eGFR, thus may associate with renoprotective effects when compared with adefovir or entecavir therapies.
authors.affiliation: Center for Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, 569 Xinsi Rd, Xi'an, China.
authors.forename: Ye
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Department of Epidemiology, School of Public Health, Fourth Military Medical University, Xi'an, China.
authors.forename: Wei-Lu
authors.initials: WL
authors.lastname: Zhang
authors.affiliation: Department of Oncology, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.|Department of Medical Quality Management, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
authors.forename: Xiao-Wen
authors.initials: XW
authors.lastname: Pang
authors.affiliation: Center for Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, 569 Xinsi Rd, Xi'an, China.
authors.forename: Lin-Xu
authors.initials: LX
authors.lastname: Wang
authors.affiliation: Center for Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, 569 Xinsi Rd, Xi'an, China.
authors.forename: Xin
authors.initials: X
authors.lastname: Wei
authors.affiliation: Center for Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, 569 Xinsi Rd, Xi'an, China.
authors.forename: Chang-Xing
authors.initials: CX
authors.lastname: Huang
authors.affiliation: Center for Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, 569 Xinsi Rd, Xi'an, China.
authors.forename: Xue-Fan
authors.initials: XF
authors.lastname: Bai
authors.affiliation: The First Brigade of Student, Fourth Military Medical University, Xi'an, China.
authors.forename: Shuai
authors.initials: S
authors.lastname: Han
authors.affiliation: Department of Pharmaceutics, Tangdu Hospital, Fourth Military Medical University, 569 Xinsi Rd, Xi'an, China. liulinna@fmmu.edu.cn.
authors.forename: Lin-Na
authors.initials: LN
authors.lastname: Liu
authors.affiliation: Center for Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, 569 Xinsi Rd, Xi'an, China. lianjq@fmmu.edu.cn.
authors.forename: Jian-Qi
authors.initials: JQ
authors.lastname: Lian
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D044466:Asian People; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D007668:Kidney / Q000187:drug effects* / Q000502:physiology; D007677:Kidney Function Tests; D009705:Nucleosides / Q000009:adverse effects / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012189:Retrospective Studies
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D009705:Nucleosides; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a
keywords: Antiviral; Chronic hepatitis B; Chronic kidney diseases; Drug; Mixed Linear Model